CoChat

Brain-derived neurotrophic factor (BDNF) and TrkB hippocampal gene expression are putative predictors of neuritic plaque and neurofibrillary tangle pathology

Open access
Ginsberg, Stephen D., Malek-Ahmadi, Michael H., Alldred, Melissa J., Chen, Yinghua, Chen, Kewei, Chao, Moses V., Counts, Scott E., Mufson, Elliott J. · 2019 · Neurobiology of Disease
Cited by 70

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Downregulation of brain-derived neurotrophic factor (BDNF) and its cognate neurotrophin receptor, TrkB, were observed during the progression of dementia, but whether the Alzheimer's disease (AD) pathological lesions diffuse plaques, (DPs), neuritic plaques (NPs), and neurofibrillary tangles (NFTs) are related to this alteration remains to be clarified. METHODS: Negative binomial (NB) regressions were performed using gene expression data accrued from a single population of CA1 pyramidal neurons and regional hippocampal dissections obtained from participants in the Rush Religious Orders Study (RROS). RESULTS: Downregulation of Bdnf is independently associated with increased entorhinal cortex NPs. Downregulation of TrkB is independently associated with increased entorhinal cortex NFTs and CA1 NPs during the progression of AD. DISCUSSION: Results indicate that BDNF and TrkB dysregulation contribute to AD neuropathology, most notably hippocampal NPs and NFTs. These data suggest attenuating BDNF/TrkB signaling deficits either at the level of BDNF, TrkB, or downstream of TrkB signaling may abrogate NPs and/or NFTs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2019.104540

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 76

  1. Abner, 2017, Outcomes after diagnosis of mild cognitive impairment in a large autopsy series, Ann. Neurol., 81, 549, 10.1002/ana.24903 · DOI · Paper page
  2. Alldred, 2008, Terminal continuation (TC) RNA amplification enables expression profiling using minute RNA input obtained from mouse brain, Int. J. Mol. Sci., 9, 2091, 10.3390/ijms9112091 · DOI · Paper page
  3. Alldred, 2009, Terminal continuation (TC) RNA amplification without second strand synthesis, J. Neurosci. Methods, 177, 381, 10.1016/j.jneumeth.2008.10.027 · DOI · Paper page
  4. Alldred, 2012, Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction, Neurobiol. Dis., 45, 751, 10.1016/j.nbd.2011.10.022 · DOI · Paper page
  5. Alldred, 2015, Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of down syndrome (DS) and Alzheimer's disease (AD), Brain Struct. Funct., 220, 2983, 10.1007/s00429-014-0839-0 · DOI
  6. Alldred, 2018, CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of down syndrome and Alzheimer's disease following maternal choline supplementation, Hippocampus, 28, 251, 10.1002/hipo.22832 · DOI · Paper page
  7. Allen, 2011, The neurotrophins and their role in Alzheimer's disease, Curr. Neuropharmacol., 9, 559, 10.2174/157015911798376190 · DOI · Paper page
  8. Alvarez, 2014, Apathy and APOE4 are associated with reduced BDNF levels in Alzheimer's disease, J. Alzheimers Dis., 42, 1347, 10.3233/JAD-140849 · DOI
  9. Arancibia, 2008, Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats, Neurobiol. Dis., 31, 316, 10.1016/j.nbd.2008.05.012 · DOI · Paper page
  10. Arango-Lievano, 2016, Deletion of neurotrophin signaling through the glucocorticoid receptor pathway causes tau neuropathology, Sci. Rep., 6, 37231, 10.1038/srep37231 · DOI
  11. Austin, 2015, The number of subjects per variable required in linear regression analyses, J. Clin. Epidemiol., 68, 627, 10.1016/j.jclinepi.2014.12.014 · DOI · Paper page
  12. Belrose, 2014, Increased pro-nerve growth factor and decreased brain-derived neurotrophic factor in non-Alzheimer's disease tauopathies, Neurobiol. Aging, 35, 926, 10.1016/j.neurobiolaging.2013.08.029 · DOI · Paper page
  13. Bennett, 2012, Longitudinal epidemiologic clinical-pathologic studies of aging and Alzheimer's disease, Curr. Alzheimer Res., 9, 617
  14. Bennett, 2002, Natural history of mild cognitive impairment in older persons, Neurology, 59, 198, 10.1212/WNL.59.2.198 · DOI · Paper page
  15. Bennett, 2012, Overview and findings from the religious orders study, Curr. Alzheimer Res., 9, 628, 10.2174/156720512801322573 · DOI · Paper page
  16. Burnouf, 2013, NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a tau transgenic model, Aging Cell, 12, 11, 10.1111/acel.12018 · DOI · Paper page
  17. Che, 2004, Amplification of transcripts using terminal continuation, Lab. Investig., 84, 131, 10.1038/labinvest.3700005 · DOI
  18. Corsetti, 2008, Identification of a caspase-derived N-terminal tau fragment in cellular and animal Alzheimer's disease models, Mol. Cell. Neurosci., 38, 381, 10.1016/j.mcn.2008.03.011 · DOI
  19. Counts, 2007, {alpha}7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease, Arch. Neurol., 64, 1771, 10.1001/archneur.64.12.1771 · DOI · Paper page
  20. Dickson, 2009, Neuropathology of non-Alzheimer degenerative disorders, Int. J. Clin. Exp. Pathol., 3, 1
  21. Donnelly-Kehoe, 2018, Looking for Alzheimer's disease morphometric signatures using machine learning techniques, J. Neurosci. Methods, 302, 24, 10.1016/j.jneumeth.2017.11.013 · DOI · Paper page
  22. Dubois, 2007, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol., 6, 734, 10.1016/S1474-4422(07)70178-3 · DOI · Paper page
  23. Forlenza, 2015, Lower cerebrospinal fluid concentration of brain-derived neurotrophic factor predicts progression from mild cognitive impairment to Alzheimer's disease, NeuroMolecular Med., 17, 326, 10.1007/s12017-015-8361-y · DOI
  24. Garzon, 2007, Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells, J. Neurosci., 27, 2628, 10.1523/JNEUROSCI.5053-06.2007 · DOI · Paper page
  25. Garzon, 2002, A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer's disease parietal cortex, J. Neurochem., 82, 1058, 10.1046/j.1471-4159.2002.01030.x · DOI · Paper page
  26. Ginsberg, 2005, RNA amplification strategies for small sample populations, Methods, 37, 229, 10.1016/j.ymeth.2005.09.003 · DOI
  27. Ginsberg, 2008, Transcriptional profiling of small samples in the central nervous system, Methods Mol. Biol., 439, 147, 10.1007/978-1-59745-188-8_10 · DOI · Paper page
  28. Ginsberg, 2014, Considerations in the use of microarrays for analysis of the CNS, Ref. Module. Biomed Res., 1
  29. Ginsberg, 2000, Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons, Ann. Neurol., 48, 77, 10.1002/1531-8249(200007)48:1<77::AID-ANA12>3.0.CO;2-A · DOI · Paper page
  30. Ginsberg, 2006, Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease, J. Neurochem., 97, 475, 10.1111/j.1471-4159.2006.03764.x · DOI · Paper page
  31. Ginsberg, 2010, Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression, Biol. Psychiatry, 68, 885, 10.1016/j.biopsych.2010.05.030 · DOI · Paper page
  32. Ginsberg, 2011, Upregulation of select Rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease, J. Chem. Neuroanat., 42, 102, 10.1016/j.jchemneu.2011.05.012 · DOI · Paper page
  33. Ginsberg, 2012, Gene expression levels assessed by CA1 pyramidal neuron and regional hippocampal dissections in Alzheimer's disease, Neurobiol. Dis., 45, 99, 10.1016/j.nbd.2011.07.013 · DOI · Paper page
  34. Ginsberg, 2019, Selective decline of neurotrophin and neurotrophin receptor genes within CA1 pyramidal neurons and hippocampus proper: correlation with cognitive performance and neuropathology in mild cognitive impairment and Alzheimer's disease, Hippocampus, 29, 422, 10.1002/hipo.22802 · DOI · Paper page
  35. Grassi, 2018, A clinically-translatable machine learning algorithm for the prediction of Alzheimer's disease conversion in individuals with mild and premild cognitive impairment, J. Alzheimers Dis., 61, 1555, 10.3233/JAD-170547 · DOI
  36. Han, 2012, Functional connectivity variations in mild cognitive impairment: associations with cognitive function, J. Int. Neuropsychol. Soc., 18, 39, 10.1017/S1355617711001299 · DOI · Paper page
  37. Han, 2015, Mild cognitive impairment is associated with poorer decision-making in community-based older persons, J. Am. Geriatr. Soc., 63, 676, 10.1111/jgs.13346 · DOI · Paper page
  38. Holsinger, 2000, Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease, Brain Res. Mol. Brain Res., 76, 347, 10.1016/S0169-328X(00)00023-1 · DOI · Paper page
  39. Iwasaki, 2012, Sendai virus vector-mediated brain-derived neurotrophic factor expression ameliorates memory deficits and synaptic degeneration in a transgenic mouse model of Alzheimer's disease, J. Neurosci. Res., 90, 981, 10.1002/jnr.22830 · DOI
  40. Jiang, 2018, Nanoformulation of brain-derived neurotrophic factor with target receptor-triggered-release in the central nervous system, Adv. Funct. Mater., 28
  41. Kim, 2009, Regression models for public health surveillance data: a simulation study, Occup. Environ. Med., 66, 733, 10.1136/oem.2008.042887 · DOI
  42. Lins, 2017, Using artificial neural networks to select the parameters for the prognostic of mild cognitive impairment and dementia in elderly individuals, Comput. Methods Prog. Biomed., 152, 93, 10.1016/j.cmpb.2017.09.013 · DOI
  43. Malek-Ahmadi, 2018, Cognitive composite score association with Alzheimer's disease plaque and tangle pathology, Alzheimers Res. Ther., 10, 90, 10.1186/s13195-018-0401-z · DOI
  44. Malek-Ahmadi, 2019, Cerebral amyloid angiopathy and neuritic plaque pathology correlate with cognitive decline in elderly non-demented individuals, J. Alzheimers Dis., 67, 411, 10.3233/JAD-180765 · DOI
  45. Mariga, 2015, Withdrawal of BDNF from hippocampal cultures leads to changes in genes involved in synaptic function, Dev. Neurobiol., 75, 173, 10.1002/dneu.22216 · DOI · Paper page
  46. Mazzaro, 2016, Tau-driven neuronal and neurotrophic dysfunction in a mouse model of early tauopathy, J. Neurosci., 36, 2086, 10.1523/JNEUROSCI.0774-15.2016 · DOI
  47. Michalski, 2015, Brain-derived neurotrophic factor and TrkB expression in the "oldest-old," the 90+ study: correlation with cognitive status and levels of soluble amyloid-beta, Neurobiol. Aging, 36, 3130, 10.1016/j.neurobiolaging.2015.08.022 · DOI · Paper page
  48. Mirra, 1991, The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease, Neurology, 41, 479, 10.1212/WNL.41.4.479 · DOI · Paper page
  49. Mitra, 2019, Innovative therapy for Alzheimer's disease-with focus on biodelivery of NGF, Front. Neurosci., 13, 38, 10.3389/fnins.2019.00038 · DOI · Paper page
  50. Mufson, 1999, Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment, Exp. Neurol., 158, 469, 10.1006/exnr.1999.7086 · DOI · Paper page
  51. Mufson, 2000, Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease, J. Comp. Neurol., 427, 19, 10.1002/1096-9861(20001106)427:1<19::AID-CNE2>3.0.CO;2-A · DOI
  52. Mufson, 2002, Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer's disease, Neurochem. Res., 27, 1035, 10.1023/A:1020952704398 · DOI
  53. Mufson, 2002, Loss of basal forebrain p75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease, J. Comp. Neurol., 443, 136, 10.1002/cne.10122 · DOI · Paper page
  54. Mufson, 2007, Cholinotrophic molecular substrates of mild cognitive impairment in the elderly, Curr. Alzheimer Res., 4, 340, 10.2174/156720507781788855 · DOI · Paper page
  55. Mufson, 2012, Mild cognitive impairment: pathology and mechanisms, Acta Neuropathol., 123, 13, 10.1007/s00401-011-0884-1 · DOI · Paper page
  56. Mufson, 2015, Hippocampal plasticity during the progression of Alzheimer's disease, Neuroscience, 309, 51, 10.1016/j.neuroscience.2015.03.006 · DOI · Paper page
  57. Mufson, 2016, Molecular and cellular pathophysiology of preclinical Alzheimer's disease, Behav. Brain Res., 311, 54, 10.1016/j.bbr.2016.05.030 · DOI · Paper page
  58. Mufson, 2016, Braak staging, plaque pathology, and APOE status in elderly persons without cognitive impairment, Neurobiol. Aging, 37, 147, 10.1016/j.neurobiolaging.2015.10.012 · DOI · Paper page
  59. Murray, 1994, Differential regulation of brain-derived neurotrophic factor and type II calcium/calmodulin-dependent protein kinase messenger RNA expression in Alzheimer's disease, Neuroscience, 60, 37, 10.1016/0306-4522(94)90202-X · DOI
  60. Nagahara, 2013, Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice, J. Neurosci., 33, 15596, 10.1523/JNEUROSCI.5195-12.2013 · DOI · Paper page
  61. Naito, 2017, Emerging roles of the neurotrophin receptor TrkC in synapse organization, Neurosci. Res., 116, 10, 10.1016/j.neures.2016.09.009 · DOI
  62. Peng, 2009, Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease, J. Neurosci., 29, 9321, 10.1523/JNEUROSCI.4736-08.2009 · DOI · Paper page
  63. Phillips, 1991, BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease, Neuron., 7, 695, 10.1016/0896-6273(91)90273-3 · DOI · Paper page
  64. Poon, 2011, Beta-amyloid impairs axonal BDNF retrograde trafficking, Neurobiol. Aging, 32, 821, 10.1016/j.neurobiolaging.2009.05.012 · DOI · Paper page
  65. Poon, 2013, Beta-amyloid (Abeta) oligomers impair brain-derived neurotrophic factor retrograde trafficking by down-regulating ubiquitin C-terminal hydrolase, UCH-L1, J. Biol. Chem., 288, 16937, 10.1074/jbc.M113.463711 · DOI · Paper page
  66. Rajagopal, 2004, Transactivation of Trk neurotrophin receptors by G-protein-coupled receptor ligands occurs on intracellular membranes, J. Neurosci., 24, 6650, 10.1523/JNEUROSCI.0010-04.2004 · DOI · Paper page
  67. Rosa, 2016, Tau downregulates BDNF expression in animal and cellular models of Alzheimer's disease, Neurobiol. Aging, 48, 135, 10.1016/j.neurobiolaging.2016.08.020 · DOI · Paper page
  68. Sen, 2017, ApoE isoforms differentially regulates cleavage and secretion of BDNF, Mol. Brain., 10, 19, 10.1186/s13041-017-0301-3 · DOI · Paper page
  69. Signaevsky, 2019, Artificial intelligence in neuropathology: deep learning-based assessment of tauopathy, Lab. Invest., 99, 1019, 10.1038/s41374-019-0202-4 · DOI · Paper page
  70. Skaper, 2008, The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors, CNS Neurol. Disord. Drug Targets, 7, 46, 10.2174/187152708783885174 · DOI · Paper page
  71. Tanila, 2017, The role of BDNF in Alzheimer's disease, Neurobiol. Dis., 97, 114, 10.1016/j.nbd.2016.05.008 · DOI · Paper page
  72. Tapia-Arancibia, 2008, New insights into brain BDNF function in normal aging and Alzheimer disease, Brain Res. Rev., 59, 201, 10.1016/j.brainresrev.2008.07.007 · DOI · Paper page
  73. Thompson Ray, 2011, Decreased BDNF, TrkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders, J. Psychiatry Neurosci., 36, 195, 10.1503/jpn.100048 · DOI · Paper page
  74. Tiernan, 2016, Protein homeostasis gene dysregulation in pretangle-bearing nucleus basalis neurons during the progression of Alzheimer's disease, Neurobiol. Aging, 42, 80, 10.1016/j.neurobiolaging.2016.02.031 · DOI · Paper page
  75. Tjur, 1998, Nonlinear regression, quasi likelihood, and overdispersion in generalized linear models, Am. Stat., 52, 222, 10.1080/00031305.1998.10480567 · DOI · Paper page
  76. Yu, 2019, Association of cortical beta-amyloid protein in the absence of insoluble deposits with alzheimer disease, JAMA Neurol., 10.1001/jamaneurol.2019.0834 · DOI

Cited by

See all 70

Metadata

Authors
Ginsberg, S. D., Malek-Ahmadi, M. H., Alldred, M. J., Chen, Y., Chen, K., Chao, M. V., Counts, S. E., & Mufson, E. J.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2019-12
Volume
132
Pages
104540
ISSN
0969-9961 (ISSN-L)
OpenAlex
W2964134247
Cited by
70
References
16
FWCI
3.00
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Aging
  • Alzheimer's Association

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Brain-derived neurotrophic factor (BDNF) and TrkB hippocampal gene expression are putative predictors of neuritic plaque and neurofibrillary tangle pathology. https://app.cochat.ai/papers/10.1016/j.nbd.2019.104540
The paper
Ginsberg, S. D., Malek-Ahmadi, M. H., Alldred, M. J., Chen, Y., Chen, K., Chao, M. V., Counts, S. E., & Mufson, E. J. (2019). Brain-derived neurotrophic factor (BDNF) and TrkB hippocampal gene expression are putative predictors of neuritic plaque and neurofibrillary tangle pathology. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2019.104540

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.